FZ 004 - Fzata
Alternative Names: FZ-004 - FzataLatest Information Update: 29 Aug 2024
Price :
$50 *
At a glance
- Originator Fzata
- Class Analgesics; Gene therapies; Probiotics; Yeasts
- Mechanism of Action Gastrointestinal microbiome modulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pain
Most Recent Events
- 29 Aug 2024 Fzata has patent protection for BioPYM technology platform in USA (Fzata pipeline, August 2024)
- 09 Aug 2024 Preclinical trials in Pain in USA (PO) before August 2024 (Fzata pipeline, August 2024)